MDK and Alzheimer disease: Figure 1 illustrates this approach using the example of compounds targeting pathological levels of midkine in the brain, for which small molecule inhibitors have been pursued as potential therapeutic interventions for AD, and which is also a target nominated by the Accelerating Medicine Partnership for AD (AMP‐AD) consortium.9, 10, 11